{
    "nctId": "NCT05762042",
    "briefTitle": "Comparison of the Efficacy and Tolerability of Femal Versus Placebo",
    "officialTitle": "Comparison of the Efficacy and Tolerability of Femal Versus Placebo in the Treatment of Hot Flashes in Patients With Previous Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Menopause",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "efficacy of Femal in reducing the mean score of vasomotor symptoms between baseline (T0) and month 3 (T2).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n- patients with a history of breast cancer, in spontaneous or iatrogenic menopause or who are premenopausal with ovarian function suppressed by GNRH analogue and experiencing severe vasomotor symptoms (at least 20 hot flushes per week).\n\nPatients who are on tamoxifen or aromatase anti-estrogen or aromatase inhibitor therapy are eligible if started at least 2 months prior to study entry\n\nExclusion Criteria:\n\n* Patients on SSRI or SNRI antidepressant therapy are excluded",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}